Elevation Oncology Announced New Preclinical Data Demonstrating The Combination Potential Of EO-3021, A Claudin 18.2 Antibody-drug Conjugate, With VEGFR2 or PD-1 Inhibitors, The Data Will Be Presented At The European Society For Medical Oncology...
Elevation Oncology Announced New Preclinical Data Demonstrating The Combination Potential Of EO-3021, A Claudin 18.2 Antibody-drug Conjugate, With VEGFR2 or PD-1 Inhibitors, The Data Will Be Presented At The European Society For Medical Oncology...
Elevation Oncology宣佈新的臨床前數據，展示了EO-3021（一個Claudin 18.2抗體-藥物結合物）與VEGFR2或PD-1抑制劑的組合潛力，這些數據將在歐洲醫學腫瘤學會大會上展示……
Elevation Oncology Announced New Preclinical Data Demonstrating The Combination Potential Of EO-3021, A Claudin 18.2 Antibody-drug Conjugate, With VEGFR2 or PD-1 Inhibitors, The Data Will Be Presented At The European Society For Medical Oncology Immuno-oncology Annual Congress 2024
Elevation Oncology宣佈新的臨床前數據，展示了EO-3021（一個Claudin 18.2抗體-藥物結合物）與VEGFR2或PD-1抑制劑的組合潛力，這些數據將在2024年歐洲醫學腫瘤學會免疫腫瘤學年會上展示。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間